China's Online Mutual Aid Market Expected to Triple to 450 Million Users by 2025
By 2025, China's online mutual aid industry is expected to reach 450 million users, or nearly 32% of the country’s population, three times the number of current users, according to the Online Mutual Aid Industry White Paper published today by the Research Institute of Ant Group (“the Institute”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200507005383/en/
White Paper Predicts Chinese Online Mutual Aid Market to Triple by 2025 (Graphic: Busness Wire)
The industry white paper, the first of its kind in China, surveyed over 58,000 users of online mutual aid on their perceptions of the industry. Nearly 80% of the respondents felt that online mutual aid platforms strengthened their sense of security. Over 53% also stated that they would consider enrolling their family members in online mutual aid programs.
Users of online mutual aid programs in China are primarily from low-income or middle-income households, according to the white paper. Among those surveyed, who took part in March this year by responding to an online questionnaire, 80% earn less than RMB 8,333 (USD 1,180) per month while 72% come from third or lower-tier cities and rural areas.
“Online mutual aid platforms have become a complementary force in China’s comprehensive healthcare system, which is comprised of both essential public coverage for all citizens and commercial health insurance,” said Zheng Bingwen, Director of the World Social Security Center at the Chinese Academy of Social Sciences and one of the advisers to the white paper.
The reimbursement rate of China’s serious disease insurance scheme, part of the public healthcare system, is capped at 60%1, leaving a portion that patients still need to pay themselves. According to the white paper, online mutual aid programs serve as a complement by further reducing out-of-pocket expenses accrued in the treatment of critical illnesses, bringing it from 40% to below 20% for patients solely dependent on public healthcare coverage.
The white paper estimates that more than 150 million users had enrolled in various online mutual aid programs in China as of the end of 2019, of which over 100 million use Xiang Hu Bao, the online mutual aid platform housed on Alipay, the world's leading open digital lifestyle platform.
Amid the Covid-19 outbreak, Xiang Hu Bao in February also introduced a temporary one-time protection scheme free of charge for all participants, offering a payout of up to RMB 100,000 (USD 14,000) if someone who takes part passes away from the infection. Payouts were entirely borne by Ant Group and Xiang Hu Bao participants did not need to bear the cost.
“As awareness and concerns about health-care needs grows in China, especially since the Covid-19 outbreak, public demand for more comprehensive and diversified healthcare coverage will continue to rise,” said Ming Yin, Vice President of Ant Group. “Online mutual aid platforms will have an increasingly important role to play in providing a basic health plan for people, who can then choose from a wide range of healthcare services and policies.”
“We are committed to serving more users across China and providing them with inclusive mutual aid programs tailored to their specific needs,” Mr. Yin said.
While nearly 70% of online mutual aid participants surveyed in the white paper said they were not covered by commercial health insurance, over 42% said they intend to purchase such insurance products in the future.
This finding is in line with a survey conducted by FT Confidential Research2 in June 2019, which found that 33% of Xiang Hu Bao’s participants intended to buy a critical illness insurance product over the next six months, versus only 22% of those who do not use the platform.
About Xiang Hu Bao
Xiang Hu Bao, which literally means “mutual protection,” was launched in October 2018 and provides its participants with a basic health plan covering 100 types of critical illness, including thyroid cancer, breast cancer, lung cancer, critical brain injury and acute myocardial infarction. All participants equally share the risk of becoming critically ill and collectively bear the related medical expenses. On the Xiang Hu Bao platform, the entire evidence submission process is powered by Alipay’s proprietary consortium blockchain technology, which ensures the process is tamper-proof and helps to increase the platform’s transparency, differentiating itself from other mutual aid platforms. While Xiang Hu Bao is not a health insurance product, it complements premium health insurance offerings in the market that have a wider range and depth of coverage.
About Alipay
Alipay is the world's leading open digital lifestyle platform operated by Ant Financial Services Group (Ant Group). In 2004, Alipay launched as an escrow service to address the issue of trust between online buyers and sellers in the early days of e-commerce in China. Continuously innovating to bring mobile payment to the world, Alipay serves more than 1.2 billion users worldwide together with its global e-wallet partners as of June 30, 2019. Alipay has evolved from a payment tool to become a one-stop digital lifestyle platform. Through an open platform strategy, it introduces service providers from sectors such as local living, public services, and financial services, to bring consumers a more comprehensive experience. Along the way, it helps merchants digitalize their operations, promoting digital transformation in the service industry.
Alipay actively shares its financial technology experience with overseas partners, in order to bring inclusive financial services to the world. Working with more than 250 overseas financial institutions, Alipay created online payment channels for buyers and sellers in more than 200 countries and regions. When Chinese people travel abroad, they can pay directly using their mobile phones, and receive dedicated local merchant services through Alipay. These services have been introduced in 56 countries and regions. Tax reimbursement via Alipay is supported in 35 countries and regions, and Alipay supports 27 different currencies. In addition, foreign tourists and foreigners living in China can also use Alipay for mobile payments in the country.
1 Source: http://www.xinhuanet.com/english/2019-05/12/c_138052821.htm
2 Source: https://www.ft.com/content/3bbf683e-a325-11e9-974c-ad1c6ab5efd1
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200507005383/en/
Contact information
Media Enquiries
Bell Wang
E: yixing.wl@antfin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Positive Phase 3 Results Support ZIIHERA ® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA ® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction, and esophagus. Both ZIIHERA plus TEVIMBRA and chemotherapy and ZIIHERA plus chemotherapy demonstrated clinically meaningful and highly statistically significant improvements in progression-free survival (PFS) compared to the control arm, trastuzumab plus chemotherapy. ZIIHERA plus TEVIMBRA and chemotherapy also demonstrated clinically meaningful and statistically significant improvements in overall survival (OS), and ZIIHERA plus chemotherapy demonstrated a clinically meaningful eff
Global Winners of the 2025–2026 World Branding Awards Announced at First-Ever Japan Ceremony17.11.2025 12:43:00 EET | Press release
Now in its 20th edition, the World Branding Awards continues to spotlight the world’s most impactful and trusted brands. This year, over 1,092 brands from 66 countries were nominated as “Brand of the Year”, with less than 100 declared Winners across Global, Regional, and National tiers. The World Branding Awards Ceremony stepped outside London for the first time, bringing its global presence to the Osaka City Museum of Fine Arts. The 2025–2026 edition welcomed over 80 international guests and was presented by the acclaimed Allie Sakakibara. The evening was further elevated by a keynote presentation from Miho Noguchi, who shared insights on building emotional resonance through immersive brand experiences. Global Tier winners celebrated their outstanding branding excellence across various industries, including IKEA (Sweden), Lurpak (Denmark), Marriott International (United Kingdom), Nike (USA), Sennheiser (Germany), and Yakult (Japan). These brands consistently demonstrated strength, inf
Henlius and Organon Announce US FDA Approval of POHERDY ® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US17.11.2025 12:30:00 EET | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.1 POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic therapies for patients with certain HER2-positive breast cancers.2 "Expanding access to treatments for diseases that disproportionately impact women, including breast cancer, the most common cancer among women in the US excluding skin cancer, is at the core of our mission,” said Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon.3 “Not only is POHERDY the first approved biosimilar to PERJETA in the US, but its approval also builds
WEX ® Unlocks Access to 20,000+ Tesla Superchargers Across Europe17.11.2025 12:15:00 EET | Press release
WEX® (NYSE: WEX), the global commerce platform that simplifies the business of running a business, today announced integration with the Tesla Supercharger network, adding over 20,000 fast-charging points across 1,500+ locations to its platform. The move significantly expands charging options for WEX’s customers, particularly in areas where high-power charging has been limited or expensive. By bringing Tesla Superchargers into their ecosystem, WEX gives drivers access to competitively priced fast charging with speeds up to 250 kW, increasing availability of high-power charging stations by 10%. WEX customers already use the EV Driver by WEX app to charge at over 1 million charging points throughout Europe. Now, they can access Tesla Superchargers with the same seamless experience: comparing real-time pricing across all networks, planning optimal routes, tracking sessions, and managing payments in one unified platform - regardless of the charging network they choose. “Providing access to
Global Cement Industry Reports 25% CO 2 Intensity Reduction and Calls for Urgent Government Action to Accelerate Net Zero Mission17.11.2025 12:00:00 EET | Press release
The extensive decarbonisation work being carried out by the global cement and concrete industry to cut CO₂ emissions is set out in a new global report launched at COP30 in Belem, Brazil. The report details latest industry data showing that the sector is making progress, and also emphasises the need for urgent global government input to help accelerate action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117920702/en/ GCCA Cement and Concrete Industry Net Zero Action and Progress Report The report finds that the industry has reduced the CO₂ intensity of cementitious products by 25% across the globe since 1990, and also sets out a series of policy recommendations that can pave the way for faster reductions. Dominik von Achten GCCA President and Chairman of the Managing Board of Heidelberg Materials said: "Our industry is collaborating and innovating across every aspect of our manufacturing – finding new ways to work and d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom